Short answer
ARTIVION, INC. (AORT) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). Artivion exercised its option to acquire Endospan after FDA approval of Nexus™ on April 2, 2026.
ARTIVION, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Artivion exercised its option to acquire Endospan after FDA approval of Nexus™ on April 2, 2026
- Base purchase price $175.0 million, funded entirely in cash, with expected net cost approximately $135.0 million after loan offsets
- Acquisition adds Nexus™ Aortic Arch Stent Graft System, expanding Artivion’s cardiovascular device portfolio following regulatory clearance
- Contingent consideration up to $200.0 million tied to Nexus™ performance, payable approximately two years after closing
- Closing remains conditional on due diligence, regulatory approvals, consents, and absence of material adverse effects
Item 2.02 · Results of Operations and Financial Condition
- Forward-looking disclosure tied to pending acquisition, financing, NEXUS™ performance, contingent consideration, and purchase-price adjustments
- Completion remains conditional, with risks of delay, failure to close, or agreement termination
- Acquisition financing includes potential borrowings under Artivion’s term loan facility
- Outcomes may vary materially due to indemnification claims, escrow recoveries, and contingent consideration-offsetof
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARTIVION, INC. 8-K filings
Get the next AORT 8-K as it lands
Follow AORT for push alerts, or ask the research agent what this filing means.